Posted on 10/11/2008 in Pharmaceutical Company Financials Shire has announced an acquisition of 5,000 American Depositary Shares.
In an announcement on the company's website, Tony Guthrie, deputy company secretary, said that it was notified by Mr David Mott, a non-executive director of the company.
The acquisition represents 15,000 ordinary shares of five pence each.
Additionally, the shares were acquired at an average price of $37.4643 (23.82 pounds) per American Depositary Share.
Following the purchase, Mr Mott now holds 20,000 of the shares in the company.
In other related Shire news, the company reported on Wednesday last week that it has successfully settled all pending litigation in connection with former shareholders of Transkaryotic Therapies.
As a result, Shire will pay the same price of $37 per share originally offered to all TKT shareholders at the time of the July 2005 merger, plus interest.
Founded in 1986, Shire is a biopharmaceutical company with revenues in 2007 at $2,436 million.
Along with a sales and marketing infrastructure with a broad portfolio of products in North America and Europe, the company has distributors in the aforementioned, as well as Australia, Hong Kong, Israel, Malaysia, Philippines, Singapore, South Africa, South Korea and Thailand. Other news stories from 10/11/2008
Read more in the Zenopa News Archive
How this news is generated
|
